May 2021 - Page 2 of 4 - PsychedelicNewsWire (PNW)

WednesdayMay 19, 2021 3:30 pm

Psychedelics Researchers Target Systemic Inflammation

While medical science is still working to establish how different cannabinoids can best be used to combat widespread/systemic inflammation, psychedelics researchers are hard at work to develop a “wonder drug” for systemic inflammation from psychedelics. An LSU Health Sciences Center team is looking into how DOI, a synthetic psychedelic substance that is similar to LSD, can be refined in order to exploit its anti-inflammatory effects. Eleusis, a life sciences company, is working with the LSU researchers. Charles Nichols is a pharmacology professor and also the scientific founder at Eleusis. He has proven that DOI is good at not only preventing…

TuesdayMay 18, 2021 2:00 pm

Harvard Scientist Sets Out to Create Psychedelic Drugs Analogues

Jonathan Sporn, a former scientist at NIH and Harvard, has announced that his new company, Gilgamesh Pharmaceuticals, has raised a total of $27 million in its Series A funding round. The firm intends to use the money collected to prepare four drug candidates for Investigational New Drug (“IND”) applications to the FDA. This isn’t the first time that Sporn is venturing into the psychedelics sector. His first foray, through Perception Neuroscience, saw his team focus all their attention on developing a mental health drug from R-ketamine to treat depression that is unresponsive to existing medications. At the beginning of 2019,…

TuesdayMay 18, 2021 9:15 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Targets Potential Expansion of Rapid COVID-19 Test Kit Distribution with Delivery of 2,000 Units to Israel

XPhyto recently delivered 2,000 of its rapid Covid-ID Lab test kits to an established Israeli distributor for clinical evaluation by the Ministry of Health The delivery, which marks entry into the Middle East, follows the approval of the test kits in Europe In an earlier interview, CEO Hugh Rogers had noted that XPhyto was looking to expand distribution to various markets, including the Middle East In an interview on Proactive on March 22, XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) CEO and Director Hugh Rogers explained the implications of the CE-IVD approval (European certification) the company’s 25-minute COVID-19 RT-PCR…

MondayMay 17, 2021 3:30 pm

Texas House Passes Psychedelics Research Law

The House of Representatives in Texas passed a bill last week that would mandate the state to undertake research regarding the potential of different psychedelic substances, such as MDMA and psilocybin. The bill, whose chief sponsor was Rep. Alex Dominguez, a Democrat, was supported by 134 House members while 12 opposed it. The passage of the bill now means it heads to the state Senate for consideration. During an earlier Public Health House Committee meeting, legislators modified the scope of this expected research to cover only military veterans suffering from PTSD rather than leaving the bill with its previously wide…

FridayMay 14, 2021 2:00 pm

Maine Senate Bill Could Legalize Psilocybin Mushroom Therapy for Adults

A bill that was recently introduced in Maine will legalize psilocybin’s therapeutic use and establish a licensed industry for the drug. Psilocybin is the main active compound found in magic mushrooms. Introduced by State Sen. Donna Bailey, the Maine Psilocybin Services Act will permit individuals aged 21 and above to legally buy psilocybin products and ingest them under the supervision of psilocybin service providers who are licensed. The measure, whose purpose is to expand the access to psilocybin to help manage depression and anxiety, along with other mental health conditions, cites no specific medical diagnosis that individuals will need in…

FridayMay 14, 2021 12:05 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Maintains Buy Rating in Recent Equity Update

April analyst reports all point to a bright future for Cybin “CYBN is a true multi-molecule company that's not being reflected in its valuation,” reports Stifel “With a relatively small 5% penetration, Cybin could achieve ~$8B in sales in the U.S. and EU5 combined,” notes Roth A series of recent analyst reports bodes well for Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics. April reports from Canaccord Genuity equity research company, Stifel GMP (https://ibn.fm/aQ9af) and Roth Capital Partners (https://ibn.fm/YkBNb) all categorize Cybin as a buy, with Stifel increasing its price target from $5 to…

ThursdayMay 13, 2021 2:30 pm

Ontario Cannabis Company Requests Government Permission to Produce, Study Psychedelic Substances

New Leaf Canada has requested an exemption under the federal drug laws to allow it to construct a lab meant for the production and study of psychedelic substances. The marijuana company, which is based in Toronto, announced that if its request is approved, the company will commence the expansion of its marijuana production facility, which is located in Norfolk Country, Ontario. The lab will adjoin its current production facility and will be utilized in the production of psilocin and psilocybin. The two substances are active compounds found in hallucinogenic mushrooms, which are currently illegal in Canada. Despite the illegal status…

ThursdayMay 13, 2021 12:05 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Builds Alliances Ahead of Psychedelic Drug Trial for Eating Disorders

Orphan-stage pharmaceutical innovator Tryp Therapeutics is dedicated to developing novel therapies for medical conditions with unmet needs Tryp’s embrace of psychedelic drug potential is demonstrated in its advancing clinical trials seeking an answer to eating disorders such as binge eating and hyperphagia The company is also developing a clinical trial to address the needs of fibromyalgia patients who often rely on opioids to relieve their symptoms Tryp has announced two new collaborations for oversight of the drug trials this month; consultants with Fluence and Clinlogix will help to ensure the quality of the tests Bioscience pharmaceutical company Tryp Therapeutics (CSE:…

WednesdayMay 12, 2021 12:15 pm

At-Home Genetics Test May Help Detect Possible Psychedelic Therapy Risks

Psychedelics are making a comeback in Western society, having started the journey to mainstream a few years ago. This renaissance has brought with it a lot of new discoveries, many of which are useful for the mental health field. As mental health disorders increase at a rather alarming rate, the research on various psychedelics as potential alternative treatments has been welcomed by many, especially those in the psychedelic field and those who would like to indulge in psychedelics as well as users of these substances. However, as with any other drug, psychedelics carry some risk, and with more jurisdictions beginning…

TuesdayMay 11, 2021 2:30 pm

Minnesota Clinic Provides Model for Therapeutic Use of Psychedelics

Since selective serotonin reuptake inhibitor antidepressants (“SSRIs”) were introduced in the late ‘80s, little has changed in how different mental health conditions are treated. The co-founder of the Institute for Integrative Therapies (“IIT”) Manoj Doss notes that there haven’t been many breakthroughs in the psychiatry field in the recent past. Doss, who is certified in both general and occupational medicine, asserts that a need exists to re-examine how mental illnesses are treated, adding that the treatments used need to be more effective. This is why he and his co-founder, Kyle Keller, are trying to approach the treatment of various mental…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: May 2021